Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

10 months ago 27
Read Entire Article
  1. Homepage
  2. Finance
  3. Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Related

Israel Q1 GDP shrinks 3.3% annualised as Iran war weighs

Israel Q1 GDP shrinks 3.3% annualised as Iran war weighs

17 minutes ago 0
Brazil’s Lula aims to develop relationship with Trump, Washington Post reports

Brazil’s Lula aims to develop relationship with Trump, Washi...

17 minutes ago 0
Analysis-Bond yield spike is risk to unprepared equities market, investors warn

Analysis-Bond yield spike is risk to unprepared equities mar...

17 minutes ago 0

Trending

1. power outage near me
2. florida gators football
3. q day
4. rededicate 250
5. bank of america 7 eleven settlement
6. national grid
7. florida
8. acc baseball tournament
9. the handmaid's tale
10. man united vs nottm forest

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

1 year ago 732
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

1 year ago 594
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

1 year ago 460
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

1 year ago 458
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

1 year ago 407
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2026. All rights are reserved